Recombinant Human Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) Protein (His-SUMO)

Name: Recombinant Human Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-09774P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q96FL9
Target Symbol	GALNT14
Synonyms	GalNAc T14; GalNAc-T14; Galnt14; GLT14_HUMAN; Polypeptide GalNAc transferase 14; Polypeptide N acetylgalactosaminyltransferase 14; Polypeptide N-acetylgalactosaminyltransferase 14; pp GaNTase 14; pp-GaNTase 14; Protein UDP acetylgalactosaminyltransferase 14; Protein-UDP acetylgalactosaminyltransferase 14; UDP GalNAc:polypeptide N acetylgalactosaminyltransferase 14 ; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 14
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	MRRLTRRLVLPVFGVLWITVLLFFWVTKRKLEVPTGPEVQTPKPSDADWDDLWDQFDERRYLNAKKWRVGDDPYKLYAFNQRESERISSNRAIPDTRHLRCTLLVYCTDLPPTSIIITFHNEARSTLLRTIRSVLNRTPTHLIREIILVDDFSNDPDDCKQLIKLPKVKCLRNNERQGLVRSRIRGADIAQGTTLTFLDSHCEVNRDWLQPLLHRVKEDYTRVVCPVIDIINLDTFTYIESASELRGGFDWSLHFQWEQLSPEQKARRLDPTEPIRTPIIAGGLFVIDKAWFDYLGKYDMDMDIWGGENFEISFRVWMCGGSLEIVPCSRVGHVFRKKHPYVFPDGNANTYIKNTKRTAEVWMDEYKQYYYAARPFALERPFGNVESRLDLRKNLRCQSFKWYLENIYPELSIPKESSIQKGNIRQRQKCLESQRQNNQETPNLKLSPCAKVKGEDAKSQVWAFTYTQQILQEELCLSVITLFPGAPVVLVLCKNGDDRQQWTKTGSHIEHIASHLCLDTDMFGDGTENGKEIVVNPCESSLMSQHWDMVSS
Expression Range	1-552aa
Protein Length	Full Length
Mol. Weight	80.3kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Displays activity toward mucin-derived peptide substrates such as Muc2, Muc5AC, Muc7, and Muc13 (-58). May be involved in O-glycosylation in kidney.
Subcellular Location	Golgi apparatus membrane; Single-pass type II membrane protein.
Protein Families	Glycosyltransferase 2 family, GalNAc-T subfamily
Database References	HGNC: 22946 OMIM: 608225 KEGG: hsa:79623 STRING: 9606.ENSP00000288988 UniGene: PMID: 29227978 The analysis showed that the "TT" genotype was associated with unfavorable overall survival (OS, P = 0.009). PMID: 27124048 miR-125a functions as tumor suppressor in ovarian cancer by targeting GALNT14. PMID: 27133078 GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. PMID: 26871639 Expression of GalNAc-T14 or HOXB9 was strongly correlated with reduced recurrence-free survival in lung adenocarcinomas. PMID: 26544896 Recurrence of mutation suggests GALNT14 as a novel gene potentially involved in neuroblastoma predisposition. PMID: 26309160 GALNT14 stimulates MMP-2 expression. PMID: 24962947 GALN14 genotype (rs9679162) was an effective predictor for therapeutic outcome in advanced hepatocellular carcinoma (HCC) patients treated by FMP chemotherapy. PMID: 23959947 Studies demonstrate that IGFBP-3 and GalNAc-T14 are colocalized in MCF-7 cells, and confirmed the interaction between IGFBP-3 and GalNAc-T14; these results reveal a minimal region of GalNAc-T14 that was sufficiently bound to the full-length IGFBP-3. PMID: 22441125 Results provide evidence that GalNAc-T14 may be a potential biomarker for breast cancer by immunohistochemistry. PMID: 20356418 GALNT14 and FUT3/6 H-scores were significantly higher in non-small cell lung cancer cell lines sensitive to dulanermin and drozitumab versus resistant cell lines PMID: 20179215 cloning and characterization; results provide evidence that pp-GalNAc-T14 is a new member of the pp-GalNAc-T family and suggest that it may be involved in the O-glycosylation in kidney PMID: 12507512 The role of GalNAc-T14 as an intracellular mediator of the effects of IGFBP-3 need to be verified in future studies. PMID: 17434446 GALNT14 may be involved in regulating the apoptotic action of IGFBP-3. PMID: 19805900

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.